NZ236295A

NZ236295A - Immunostimulant containing n-acetyl muramylpeptides derived from cell walls of lactic acid bacteria using lysozyme

Info

Publication number: NZ236295A
Application number: NZ236295A
Authority: NZ
Inventors: Harriet Link; Jean-Jacques Pahud
Original assignee: Nestle Sa
Priority date: 1989-12-13
Filing date: 1990-11-30
Publication date: 1993-04-28
Also published as: US5185321A; DE69022005T2; DK0432490T4; CA2030951C; NO310498B1; NO905228D0; ZA909658B; JPH03255034A; DE69022005T3; EP0432490A3; AU643728B2; AU6702190A; PT96167B; ES2076280T3; DE69022005D1; GR3017428T3; CA2030951A1; EP0432490B1; PT96167A; MX172984B

Abstract

Immunostimulant products are prepared by adding lysozyme to a culture of L.bulgaricus at a pH of from 4-8 and then incubating the culture to hydrolyze peptidoglycans of cell walls of the bacteria. A suspension containing the lysozyme-treated L.bulgaricus is collected, which is centrifuged to obtain an immunostimulant supernatant. The supernatant may be filtered to obtain an immunostimulant solution, which may be added to a fermented milk, or to a whey, to prepare an immunostimulant product. Alternatively, L.bulgaricus may be cultured and hydrolyzed by lysozyme in a milk product to provide an immunostimulant milk product.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £36295 o Priority Dole's): . ^ >.V; ?.cl Compieie Specification Filed: .v9.VTw. Cioss: /X"I IStav. V1!1 S^; 5... . cjxk! fov p 28'APR 1993 " Publication Dato: P.O. Journal, No: Ifkl HU 23 6 2 95 I r • v VT-Z-n* OFFICE Patents Form No. 5 G NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION o IMMUNOMODULATION WE, SOCIETE DES PRODUITS NESTLE S.A., a Swiss company of Entre-deux-Villes, Vevey, SWITZERLAND hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: - 1 - (followed by page la) 2362 9 lcj This invention relates to an immunostimulant, to a process for its production and to the use of the immuno-stimulant and/or the process in the field of fermented milks. 5 It is known that an anticarcinogenic agent can be produced by a process comprising the steps of cultivating a lactobacillus, particularly Lactobacillus bulgaricus, hydrolyzing the lactobacillus with a proteolytic enzyme and extracting from the hydrolyzate a product rich in protein 10 and ribonucleic acid which shows anticarcinogenic activity. In addition, it is known that a milk-based dietetic product for infants can be produced by a process in which a milk acidified by Lactobacillus acidophilus is supplemented with oligoelements, vitamins and a lysozyme solu-15 tion. The lysozyme solution is intended to replace the lysozyme present in maternal milk and to improve the keeping qualities, the taste and the texture of this dietetic product. The object of the present invention is to provide an 2 0 effective immunostimulant which can be obtained from a lactic bacterium and which is particularly suitable for use in the field of fermented milks. W To this end, the immunostimulant according to the invention comprises N-acetyl muramyl peptides derived by 25 hydrolysis with lysozyme from peptidoglycans from the cell wall of lactic bacteria sensitive to lysozyme, particularly Lactobacillus bulgaricus. 'w1 Similarly, in the process for the production of an immunostimulant according to the present invention, the 30 peptidoglycans from the cell wall of lactic bacteria sensitive to lysozyme, particularly Lactobacillus bulgaricus, are hydrolyzed with lysozyme to derive N-acetyl muramyl peptides therefrom. It has been found that an agent of the type in question has a remarkable stimulating 35 effect on the immune response, particularly on the immune (followed by page 2) 236295 2 response to gram-negative enteropathogenic bacteria, such as E. coli for example. The immunostimulant according to the invention is particularly suitable for use in a fermented milk, particularly in a yoghurt or in a whey product. Similarly, the process according to the invention is suitable for use, i.e. may be directly carried out, in the production of a fermented milk, particularly a yoghurt, or in the production of a whey product. Accordingly, the present invention also relates to these uses. In the context of the invention, the immunostimulant effect of the product according to the invention is qualitatively estimated in tests on mice. It is known that, although the resuls of such tests cannot be directly applied to man, they nonetheless provide useful information. In the context of the invention, the expression "lactic bacteria sensitive to lysozyme" is used in the sense of lactic bacteria of which the cell wall comprises peptidoglycans hydrolyzable by lysozyme, i.e. degradable into N-acetyl muramyl peptides under the effect of lysozyme. The process according to the invention may be carried out using a pure culture or suspension of a lactic bacterium sensitive to lysozyme or a mixed culture or suspension comprising bacteria sensitive and non-sensitive to lysozyme. It is possible in particular to use a pure culture of Lactobacillus bulgaricus or a mixed culture of Lactobacillus bulgaricus and Streptococcus thermophilus, i.e. a yoghurt culture, for example of the commercially available type. More particularly, it is possible to use a culture or a suspension containing 106-1010 cells of lactic bacterium sensitive to lysozyme per ml. To produce a desired quantity of cells in a sufficient concentration, a suitable 236 2 3 culture medium may be inoculated with a seed culture of the bacterium in question and incubated at a temperature and at a pH favourable to the growth of the bacterium over a period of time sufficient to re-establish in the culture medium a concentration of cells comparable with that of the starting culture. The culture medium may be, for example, a milk-based medium, such as skimmed or unskimmed cow's milk, a whey, an ultrafiltration permeate, or a synthetic medium. A culture of L. bulgaricus is preferably used. To prepare this culture, a cow's milk or a synthetic medium, such as the MRS medium (Difco) for example, may be inoculated with a seed culture of this microorganism and incubated for 3 - 6 h at 37 - 45'C. If the culture is incubated for less than 3 h or at a temperature below 37"C, it is in danger of remaining in so-called latent phase, i.e. the starting phase of multiplication of the microorganism, or of not being involved long enough in the so-called exponential phase, i.e. the phase of exponential multiplication of the microorganism. On the other hand, if the culture is incubated for more than 6 h, it is in danger of entering the stationary phase, i.e. the phase in which multiplication of the microorganisms stops and during which the composition of the cell wall can change unfavourably. Finally, beyond 45°C, the temperature is no longer favourable to the growth of L. bulgaricus. The hydrolysis step is then carried out with lysozyme. The lysozyme may emanate from any suitable source, more particularly from rennet, particularly ruminant (above all bovine) rennet, or from egg white, optionally in pure form. In one particular embodiment of the process according to the invention, the rennet is used as such, i.e. without the lysozyme separated therefrom. The peptidoglycans from the cell wall of the lactic 226 2 O /"•s bacteria mentioned may be hydrolyzed for 1 to 48 h and preferably for 12 to 24 h at 15 to 37 °C using 1 to 500 jig lysozyme per ml of a culture containing 10® to 1010 cells of these bacteria per ml, for example at a pH value favourable 5 to the action of the lysozyme used. This pH is of the order of 4 to 6 for a lysozyme of rennet and of the order of 6 to 8 for a lysozyme of egg white for example. For the uses according to the invention, it is possible on the one hand to add the immunostimulant either as 10 such or in the form of an aqueous extract to a fermented milk, such as a liquid or stirred yoghurt, or to a whey product, such as a whey-based beverage. The quantity of agent added may correspond, for example, to the quantity of N-acetyl muramyl peptides derived from the walls of 106-1010 15 cells of lactic bacteria sensitive to lysozyme per ml of said fermented milk or said whey product. On the other hand, the hydrolysis step may be carried out, for example, in a fermented milk, more particularly in a milk fermented by L. bulgaricus on its own or in combin-20 ation with S. thermophilus, or in a lactoserum. In the case of the fermented milk, the lysozyme may be added to the milk before, during or after its fermentation, for example in a quantity of approximately 1 to 500 fig lysozyme per ml milk. In the case of whey, the above-mentioned 25 bacteria sensitive to lysozyme may be added to the whey or, where appropriate, may even be cultivated thereon and, if necessary, lysozyme may be added. The invention is illustrated by the following Examples in which percentages are by weight, unless otherwise indi-3 0 cated. The immunostimulating effect, i.e. the stimulating effect on the immune response, is estimated by determination of concentrations of specific antibodies in mice by the ELISA test. 3 5 The ELISA test, which is well known to the expert, 23 6 2 9 comprises detecting an enzyme marking an anti-antibody which attaches itself to a specific antibody of an immunoglobulin, such as IgG, IgM or IgA, which in turn attaches itself to an antigen, such as a bacterial antigen for ex-5 ample, which is itself fixed to a support insoluble in aqueous medium. Example 1 A synthetic culture medium is prepared, consisting of 10 a modified MRS medium (Difco Lab. , USA) which has the following composition (expressed in g dry matter per litre medium): Protein hydrolyzate 10 Meat extract 10 15 Yeast extract 5 Glucose 20 Lactose 10 Emulsifier 1 Ammonium citrate 2 20 Sodium acetate 5 MgS04 0.1 MnSO* in o • o K2HP04 2 This synthetic culture medium has a pH of 6.5. It is 25 sterilized for 15 mins. at 121°C and then inoculated with a seed culture of Lactobacillus bulgaricus, in the present case a culture of L. bulgaricus NCDO 1489 (National Collection of Food Bacteria, AFRC Institute of Food Research, Reading Laboratory, Shinfield, Reading, RG2 9AT, UK). 30 The culture is incubated for 6 h at 40°C. The biomass is separated, washed and divided into 2 parts A and B. Part A is suspended in a 0.02 M phosphate buffer at pH 7 while part B is suspended in a 0.01 M acetate buffer at pH 5 in a quantity of 2.109 cells of the microorganism per ml. 35 The L. bulgaricus cells of suspension A are hydrolyzed 2362! with a commercially available lysozyme from egg white (Calbiochem, Federal Republic of Germany). The L. bulgaricus cells of suspension B are hydrolyzed with a rennet lysozyme extracted and purified as described by J.J. Pahud 5 et al., in Biochem. J. 201. 661-664 (1982). To this end, 16 fig lysozyme are added per ml suspension and incubated for 18 h at 25 "C. The suspension is then centrifuged and the supernatant phase is filtered through a membrane having 0.4 5 /im diameter pores. 10 Two immunostimulants A and B are thus obtained in the form of sterile solutions or extracts containing the N-acetyl muramyl peptides derived from the cell walls of 2.109 L. bulgaricus cells per ml by hydrolysis with lysozyme from egg white (A) or from rennet (B). 15 The immunostimulating effect of the agents A and B is determined in mice of the "Swiss white" species (Tutt-lingen, Federal Republic of Germany) using the following experimental procedure: Six groups numbered 1 to 6 each comprising six mice 20 weighing 18 - 2 0 g are given a normal diet and water ad lib. Starting from the beginning of the test on day 0, oral intubations are carried out on days 1, 3, 5, 15, 17, 19 and 30. The food and the water are removed from the mice 3 h before each of these intubations and are returned 25 immediately afterwards. Sera are taken from the mice on days 0, 29 and 40. Intestinal washing is carried out on day 40. Each oral intubation is carried out with a dose of 0.5 ml per mouse. The composition of these doses is the same 3 0 for the mice of the same group, but varies from group to group in accordance with Table I below. In Table I, the word "vaccine" indicates that 5.109 cells of Eschericia coli 0111 :K58 have been suspended per dose, one half of the cells having been inactivated for 1 h at 100°C and the 35 other half having been inactivated with a 0.05% solution of o 5 10 15 20 .4 25 2362 glutaraldehyde (Hilpert et al., Food and Immunology, 1977, Ed. L. Hambraeux, L.A. Hanson, H. McFarlane, Swedish Nutrition Foundation Symposium XIII, 182-196). The letters CT stand for cholera toxin, an immunostimulant well known to the expert. The expression "physiological solution" stands for distilled water containing 0.9% NaCl. Table I Group Basic liquid 1 2 3 4 5 6 Physiological solution tl II II Immunostimulant A Immunostimulant B Substances added NaHCOj Others % 3 3 3 3 3 3 Vaccine Vaccine Vaccine Vaccine 1 /xg CT 1 jug CT The concentration of IgG and IgM antibodies in the sera and the concentration of IgG and IgA antibodies in the intestinal washing fluids taken from the mice are determined by the ELISA test. Table II below shows the relative values obtained. The figures shown are a geometric mean of the values determined for each of the six mice of one and the same group. The asterisks indicate that, for the figures thus marked, the probability that an error has been made in claiming they are different from the corresponding figure (same column) of group 3 (control, mice which have only been given the vaccine) is less than 5%. In other words, for the figures marked with an asterisk, the value "p", determined by unilateral variance analysis, is smaller than 0.05. 35 23 6 2 55 8 Table II Group Ex sera: Ex intestinal fluid: IgG IgM IgG IgA d29 d40 d29 d4 0 d40 d40 1 69 57 36 39 8 8 2 96 94 25 80 10 11 3 189 489 31 83 11 18 4 572* 759 113 123* 13 24 5 525* 828 104 141* 18 53* 6 397* 1362* 39 45 24* 72* It can be seen that the sera removed on days 29 and 4 0 show an increase by a factor of approximately 2-3 in the concentration of IgG antibodies for the mice which were given the vaccine and immunostimulant A or B (invention, groups 5 and 6) or CT (comparison, group 4) in relation to the mice which were only given the vaccine (control, group 3) . By contrast, an increase in the concentration of IgM antibodies is only observed for immunostimulant A (invention, group 5) and CT (comparison, group 3) . The concentration of IgG and IgA antibodies in the intestinal fluids of the mice given the vaccine and immunostimulant A or B (invention, groups 5 and 6) also shows a very distinct increase in relation to that of the intestinal fluids of the mice given the vaccine alone (control, group 3). Example 2 A biomass of L. bulgaricus is prepared in the same way as described in Example 1. The biomass is suspended in a 0.01 M acetate buffer at pH 5 in a quantity of 1.6.109 cells of the microorganism per ml. SSfP^fe,-. © 23 62 rO 1% Liquid rennet containing 4% lysozyme (Laboratoire Presure Granday, Beaune, France) is added to the suspension, followed by incubation with gentle stirring for 18 h at 25°C. The suspension is then centrifuged and the super-5 natant phase is filtered through a membrane having 0-45 ^tm diameter pores. An immunostimulant C is thus obtained in the form of a sterile solution or extract containing the N-acetyl muramyl peptides derived from the cell walls of 1.6.109 10 cells of L. bulgaricus per ml by hydrolysis with rennet lysozyme in the form of rennet itself. The immunostimulating effect of immunostimulant C is verified in mice of the "Swiss white" species in a similar manner to Example 1, except that the immunostimulant is not 15 administered to the mice by intubation, but is added to the water which they drink freely in a quantity of 1 part immunostimulant to 50 parts water. Throughout the test, 10 ml lipid per 24 h are placed at the disposal of the mice of which the daily requirement is approximately 4-7 ml. 2 0 Four groups of six mice each numbered 1 to 4 are given a normal diet. Two of these groups receive physiological solution ad lib. The other two are given physiologi cal solution to which immunostimulant C has been added. In addition, the mice of two of these groups are also given a 25 vaccine of E. coli by oral intubation in a similar manner to that described in the experimental procedure of Example 1. Table III below summarizes the feeding and/or vaccination program for the mice of the various groups. 30 ... 10 2362 /">> 10 Table III Group 1 Liquid Physiological solution Physiological solution + immunostimulant C Physiological solution + immunostimulant C Physiological solution + immunostimulant C Intubation Vaccine Vaccine The concentration of IgG and IgM antibodies in the sera and the concentration of IgA antibodies in the intes-15 tinal washing fluids taken from the mice are determined by the ELISA test. Table IV below shows the relative values obtained. 20 25 30 Table IV Group Ex sera Ex intestinal fluid IgG IgM IgA d29 d40 d29 d40 d40 1 77 68 54 101 2 2 96 78 37 66 3 3 1427 1213 71 94 25 4 2365 3180* 219* 360** 31 * value "p" = 0. 065 ** value "p" = 0. 014 It can be seen that the sera removed on days 29 and 40 35 show an increase by a factor of approximately 2-3 or even more in the concentration of IgG and IgM antibodies for the mice which were given the vaccine and which drank water containing immunostimulant C (invention, group 4) in relation to the mice which were given the vaccine alone 2362 11 (control, group 3). By contrast, there is hardly any difference between the concentrations of IgA antibodies for the mice of these groups 3 and 4. Example 3 A cow's milk is inoculated with 3% by volume of a pure commercially available seed culture containing approximately 108 cells of Lactobacillus bulgaricus per ml. The culture thus inoculated is then incubated for 5 h at 40°C. A pure culture of L. bulgaricus containing approx. 10® cells of this microorganism per ml and having a pH of 4.6 is obtained. 20 fxg/ral rennet lysozyme are added to the culture which is then incubated for 12 h at 25"C. An immunostimulant is thus obtained which contains per ml the N-acetyl muramyl peptides derived from the peptidoglycans from the walls of 108 cells of L. bulgaricus by hydrolysis with rennet lysozyme. Example 4 A pure culture of L. bulgaricus is prepared in the same way as described in Example 3. 1% Liquid rennet itself containing approximately 4% lysozyme is added to the culture which is then incubated for 8 h at 20°C. An immunostimulant is thus obtained which contains per ml the N-acetyl muramyl peptides derived from the peptidoglycans from the walls of 10s cells of L. bulgaricus by hydrolysis with rennet lysozyme. Example 5 A cow's milk is inoculated with 5% by volume of a mixed seed culture containing per ml approximately 5.107 cells of Lactobacillus bulgaricus and approximately 2.10® cells of Streptococcus thermophilus obtained from commer- 236295 12 cially available cultures. A yoghurt containing approximately 2.107 L. bulgaricus cells and approximately 108 S. thermophilus cells per ml is obtained after incubation for 3 h at 43'C. 50 M9 rennet lysozyme are added to this yoghurt per ml. The yoghurt is then incubated for 12 h at 25*C and cooled to 4"C. A product of the yoghurt type having the properties of an immunostimulant is thus obtained, containing per ml the N-acetyl muramyl peptides derived from the peptidoglycans from the walls of 2.107 L. bulgaricus cells by hydrolysis with rennet lysozyme. Example 6 A yoghurt is obtained in the same way as described in Example 5. 1% Liquid rennet containing 4% lysozyme is added to this yoghurt which is then incubated for 24 h at 25*C. A product of the yoghurt type having the properties of an immunostimulant is thus obtained, containing per ml the N-acetyl muramyl peptides derived from the peptidoglycans from the walls of 2.107 L. bulgaricus cells by hydrolysis with rennet lysozyme. Example 7 The product obtained in Example 6 is centrifuged and the whey is collected. The whey itself represents an immunostimulant rich in N-acetyl muramyl peptides derived from peptidoglycans from the cell walls of L. bulgaricus by hydrolysis with rennet lysozyme. Example 8 A sweet whey from cheese production is inoculated with a seed culture of Lactobacillus bulgaricus and then incubated for 6 h at 42°C. </div>

Claims

2362 13 After cooling to 25°C, 1% rennet itself containing 4% lysozyme is added, followed by incubation for 18 h at 25°C. The immunostimulant thus obtained is rich in N-acetyl muramyl peptides derived from peptidoglycans from the cell walls of L. bulgaricus by hydrolysis with rennet lysozyme. 14 WHAT WE CLAIM IS:

1. An immunostimulant containing N-acetyl muramyl pep-tides derived by hydrolysis with lysozyme from peptidoglycans from the cell walls of lactic bacteria sensitive to 5 lysozyme.

2. An immunostimulant as claimed in claim 1, characterized in that the bacterium sensitive to lysozyme is Lactobacillus bulgaricus.

3. An immunostimulant as claimed in claim 1 which stimu-10 lates the immune response to gram-negative enteropathogenic bacteria.

4. An immunostimulant as claimed in claim 1 which stimulates the immune response to E. coli.

5. A process for the production of an immunostimulant, in 15 which the peptidoglycans from the cell walls of lactic bacteria sensitive to lysozyme are hydrolyzed with lysozyme to derive N-acetyl muramyl peptides therefrom.

6. A process as claimed in claim 5, in which the lactic bacterium sensitive to lysozyme is Lactobacillus bulgari- 20 cus.

7. A process as claimed in claim 5, in which the lysozyme Z~\ is a rennet lysozyme in purified form or in the form of rennet itself.

8. A process as claimed in claim 5, in which the lysozyme -25 is a lysozyme from egg white.

9. A process as claimed in claim 6, in which L. bulgari-cus cells to be hydrolyzed are prepared by inoculation of a cow's milk or a synthetic culture medium with a seed culture of said microorganism and the culture medium thus 3 0 inoculated is incubated for 3 - 6 h at 37 - 45°C.

10. A process as claimed in claim 5, in which the hydrolysis step is carried out for 1 - 24 h at 15 - 37" C using 1 - 500 /ig lysozyme per ml of a culture containing, per ml, 106-1010 cells of a lactic bacterium sensitive to lysozyme. 35

11. The use of the immunostimulant claimed in claim 1 in 1 /VPPT ->r f MAR 1:993 15 a fermented milk or in a whey product.

12. The use of the process claimed in claim 5 in the production of a fermented milk or in the production of a whey product.

13. The use according to claim 11 or claim 12 in which the fermented milk is a yoghurt.

14. An immunostimulant as claimed in claim 1, substantially as herein described with reference to any example thereof.

15. A process for the production of an immunostimulant as claimed in claim 5, substantially as herein described with reference to any example thereof. SOCIETE DES PRODUITS NESTLE S.A. By Their Attorneys BALDWIN SON & CAREY